Celldex Reports Third Quarter Financial Results and Provides Corporate Update
Higher development and commercial-planning expenses accompanied clinical progress; Celldex expects its funding to support planned operations through 2028.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Celldex (NASDAQ: CLDX) reported third-quarter financial results and progress toward a planned regulatory submission for barzolvolimab in chronic spontaneous urticaria (CSU). Both Phase 3 CSU studies met their primary and all key secondary endpoints across both dose groups. Efficacy persisted or deepened through Week 24; treatment continues to Week 52. Celldex anticipates a biologics license application in 2027.
Third-quarter net loss widened to $75.557 million from $67.044 million, while loss per share narrowed to $0.96 from $1.01. Cash, cash equivalents and marketable securities fell to $650.3 million from $717.6 million at June 30; Celldex expects funding to support planned operations through 2028. Phase 3 cold urticaria and symptomatic dermographism enrollment continues. Atopic dermatitis data are expected in late 2026, while the Phase 2 prurigo nodularis study is being discontinued.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointBarzolvolimab Phase 3 CSU studies met primary and all key secondary endpoints across both dose groups.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Barzolvolimab CSU regulatory application is anticipated in 2027; trial treatment continues through 52 weeks.
- Moderate pointPhase 2 cold urticaria and symptomatic dermographism met all primary and secondary endpoints, with efficacy sustained through 20 weeks.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Celldex expects available funding to support estimated working capital requirements and planned operations through 2028.
- Minor pointPhase 3 CSU efficacy persisted or deepened through Week 24, with a favorable reported safety profile.
12 minor points
- Minor pointPhase 3 CSU benefit extended to severe disease, severe angioedema and omalizumab-refractory patients.
- Minor pointPhase 2 CSU results showed sustained or deepening efficacy and a well-tolerated safety profile over 52 weeks.
- Minor pointPhase 2 CSU complete response persisted in over 40% of patients receiving 150mg every four weeks at Week 76.
- Minor pointPhase 2 CSU patients with baseline angioedema remained angioedema-free in up to 64% at Week 76.
- Minor pointPhase 3 cold urticaria and symptomatic dermographism study has ongoing enrollment.
- Minor pointBarzolvolimab retreatment achieved similar efficacy to first exposure in cold urticaria and symptomatic dermographism.
- Minor point. Forward-looking: it has not happened yet and may not happen.Atopic dermatitis Phase 2 enrollment is complete; topline data are expected in late 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional barzolvolimab indications are planned for announcement by year-end 2026.
- Minor pointCDX-622 Phase 1 healthy-volunteer results showed dose-dependent, durable serum tryptase reductions without affecting other KIT-dependent functions.
- Minor pointCDX-622 was well-tolerated at all dose levels, with extended half-life and exposure after subcutaneous administration.
- Minor point. Forward-looking: it has not happened yet and may not happen.CDX-622 asthma Phase 1 study is ongoing; Celldex plans expansion into allergic rhinitis and food allergy.
- Minor pointThird-quarter investment and other income rose to $6.694 million from $6.573 million a year earlier.
Negative
- Moderate pointResearch and development expenses rose to $67.407 million quarterly and $207.950 million year-to-date, versus $62.931 million and $169.741 million.
- Moderate pointPrurigo nodularis Phase 2 study is being discontinued following results suggesting mast cells may not drive the disease.
- Minor pointThird-quarter net loss widened to $75.557 million from $67.044 million; per-share loss narrowed to $0.96 from $1.01.
- Minor pointNine-month net loss widened to $227.745 million from $177.440 million; per-share loss increased to $3.06 from $2.67.
- Minor pointCash, equivalents and marketable securities fell to $650.3 million from $717.6 million at June 30, 2026.
4 minor points
- Minor pointThird-quarter operating activities used $65.0 million in cash.
- Minor pointNine-month revenue fell to $37,000 from $1.424 million; third-quarter revenue remained zero.
- Minor pointGeneral and administrative expenses rose to $14.844 million quarterly and $39.396 million year-to-date, versus $10.686 million and $31.897 million.
- Minor pointNine-month investment and other income declined to $19.564 million from $22.774 million.
Key Figures
- Cash and marketable securities
- $650.3 million
- September 30, 2026
- Cash used in operating activities
- $65.0 million
- Third quarter 2026
- R&D expenses
- $67.4 million (vs. $62.9 million)
- Third quarter 2026 vs. third quarter 2025
- G&A expenses
- $14.8 million (vs. $10.7 million)
- Third quarter 2026 vs. third quarter 2025
- Net loss
- $75.6 million
- Third quarter 2026
- Net loss per share
- ($0.96)
- Third quarter 2026
- Funding outlook
- Through 2028
- Current planned operations
- Anticipated BLA submission
- 2027
- Barzolvolimab in CSU
Previous Earnings Reports
-
Reported Q2 cash balance of $717.6 million and funding through 2028.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
monoclonal antibody medical
pharmacokinetics medical
pharmacodynamics medical
placebo-controlled medical
open-label medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Best-in-disease results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies showed rapid, profound, sustained efficacy supporting barzolvolimab’s potential to be a transformational therapy in CSU
- BLA submission for barzolvolimab in CSU anticipated in 2027
- Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling
- Excellent progress across all earlier stage pipeline programs
HAMPTON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2026 and provided a corporate update.
“Barzolvolimab has significant potential to address enormous populations of high unmet need and shift the treatment paradigm goal from symptom improvement to complete symptom resolution, which for patients means no itch, no hives, no swelling,” said Anthony Marucci, Co-founder, President and Chief Executive Officer at Celldex. “This quarter we reported best-in-disease results from our two Phase 3 studies in CSU, demonstrating barzolvolimab’s unparalleled ability to deliver complete response to patients—including even in patient populations suffering with severe disease or severe angioedema or with omalizumab refractory disease. We are moving quickly to bring this much needed medicine to patients and physicians. We are also making excellent progress advancing our ongoing Phase 3 study in symptomatic dermographism and cold urticaria and look forward to updating on these programs in 2027.
“Building on our leading science clinically validating the therapeutic potential of KIT inhibition in immune and inflammatory diseases, we will continue to chart the future of mast cell medicine, expanding barzolvolimab and CDX-622 development across a diverse spectrum of immune and inflammatory diseases and adding to our growing mast cell targeted pipeline to bring our science to additional patient populations that could benefit.”
Recent Program Highlights
Barzolvolimab - KIT Inhibitor Program
Barzolvolimab is a first-in-class humanized monoclonal antibody with a novel mechanism of action that targets mast cells by binding with high specificity to a unique part of the KIT receptor and potently inhibiting its activity. The KIT receptor is abundantly expressed by mast cells and critical for their function and survival. Mast cells are drivers of inflammatory responses such as hypersensitivity and allergic reactions and, in certain inflammatory diseases, such as chronic urticarias, mast cell activation plays a central role in the onset and progression of the disease.
Chronic Urticarias
- In September 2026, the Company reported best-in-disease topline results from the Phase 3 EMBARQ-CSU1 and -CSU2 studies of barzolvolimab in patients with CSU whose symptoms are inadequately controlled by H1-antihistamines. The primary and all key secondary endpoints across both studies and both dose groups were met. Results showed rapid, profound, and sustained efficacy, including unprecedented complete response rates, supporting barzolvolimab’s potential to be a transformational therapy in CSU. Efficacy was sustained or deepened from Weeks 12 to 24, and barzolvolimab was well-tolerated with a favorable safety profile through 24 weeks, consistent with prior studies. Statistically significant and clinically meaningful benefit was also seen in antihistamine refractory patients with severe disease or severe angioedema, as well as in patients with CSU refractory to omalizumab. Treatment in both EMBARQ-CSU trials will continue to 52 weeks, and the Company anticipates a BLA submission in 2027.
Data from the Phase 3 studies reported to date are consistent with results from the completed Phase 2 CSU study. In Phase 2, the primary endpoint was met at Week 12 and patients on study continued to receive barzolvolimab for a total of 52 weeks of treatment. Sustained and deepening disease efficacy and a well-tolerated long term safety profile were demonstrated over the 52-week treatment period. In addition, at 76 weeks, 7 months after the completion of dosing with barzolvolimab, over40% of patients (150mg Q4W) continued to experience profound, sustained complete response and up to64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free, supporting barzolvolimab’s disease modifying potential.
- Enrollment is ongoing in Celldex’s global Phase 3 study in cold urticaria (ColdU) and symptomatic dermographism (SD)—EMBARQ-ColdU and -SD. Barzolvolimab is the first drug in development to demonstrate clinical benefit in patients with ColdU and SD in a large, randomized, placebo-controlled study. In the Phase 2 study, all primary and secondary endpoints were met with high statistical significance at 12 weeks and sustained through the end of the 20-week treatment period. Patients with disease recurrence during the main study follow-up period qualified for an Open Label Extension (OLE). Barzolvolimab retreatment achieved similar profound efficacy to first exposure in patients with ColdU and SD.
Additional Indications
Celldex has clinically validated the therapeutic potential of the novel KIT inhibition mechanism of action with barzolvolimab and continues to grow the Company’s pipeline across a diverse spectrum of immune and inflammatory diseases where mast cells are a critical driver.
- Additional indications for barzolvolimab will be announced by year end.
- Enrollment is complete in the Phase 2 study in atopic dermatitis (AD). This randomized, double-blind, placebo-controlled, parallel group study is evaluating the efficacy and safety profile of barzolvolimab in patients with moderate to severe AD. Topline data from this study are expected to be presented in late 2026.
- Topline data from the Phase 2 study in prurigo nodularis (PN) were presented in July 2026 and suggested that mast cells may not be the key pathogenic driver in PN. Based on these results, Celldex is discontinuing the Phase 2 PN study. Barzolvolimab was well-tolerated and demonstrated a favorable safety profile consistent with prior studies.
Novel Bispecific Antibody (BsAb) Platform
Celldex continues to drive groundbreaking science and is the first company to directly demonstrate that neutralizing soluble stem cell factor (SCF) can selectively inhibit KIT signaling in mast cells—a historically challenging target. Celldex's approach provides a clinically-validated anchor mechanism that enables the development of diverse BsAb candidates where a dual mechanism approach may overcome the heterogeneity inherent in the pathophysiology of many inflammatory disorders, expanding into new indications and broader patient populations that can benefit from our medicines. CDX-622 is the first candidate from this leading science, with additional BsAbs soon to follow.
- CDX-622 (SCF & TSLP) targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. Combined neutralization of soluble SCF and TSLP with CDX-622 is expected to simultaneously reduce tissue mast cells and inhibit Type 2 inflammatory responses, allowing for a complementary dual mechanism approach that may overcome the heterogeneity inherent in the pathophysiology of many inflammatory disorders. Results from the Phase 1 trial in healthy volunteers demonstrated rapid, profound, dose-dependent, and durable reductions in serum tryptase, without impacting other KIT-dependent functions. CDX-622 also exhibited monoclonal antibody-like pharmacokinetics, with extended half-life and good exposure with subcutaneous administration, consistent with good bioavailability. CDX-622 was well-tolerated in all study parts and at all dose levels.
- An open-label, single-dose Phase 1 proof of mechanism (POM) study is ongoing to assess the safety, pharmacodynamics, and pharmacokinetics of CDX-622 in adults with mild to moderate asthma. The Company plans to advance expansion into additional indications with CDX-622, including allergic rhinitis and food allergy.
Third Quarter 2026 Financial Highlights and 2026 Guidance
Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2026 were
Revenues: No material revenue was recognized in the third quarter of 2026 or the nine months ended September 30, 2026, compared to
R&D Expenses: Research and development (R&D) expenses were
G&A Expenses: General and administrative (G&A) expenses were
Net Loss: Net loss was
Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2026 are sufficient to meet estimated working capital requirements and fund current planned operations through 2028.
About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com.
Forward Looking Statement
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159) and CDX-622, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our current expectations regarding the submission of a Biologics License Application (“BLA”) to the FDA in 2027; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contacts
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Elizabeth Higgins
Executive Director, Investor Relations & Corporate Communications
(857) 404-2088
ehiggins@celldex.com
| CELLDEX THERAPEUTICS, INC. | |||||||||||||||||
| (In thousands, except per share amounts) | |||||||||||||||||
| Three Months | Nine Months | ||||||||||||||||
| Consolidated Statements of Operations Data | Ended September 30, | Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| (Unaudited) | (Unaudited) | ||||||||||||||||
| Revenues: | |||||||||||||||||
| Product development and licensing agreements | $ | - | $ | - | $ | 7 | $ | 57 | |||||||||
| Contracts and grants | - | - | 30 | 1,367 | |||||||||||||
| Total revenues | - | - | 37 | 1,424 | |||||||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | 67,407 | 62,931 | 207,950 | 169,741 | |||||||||||||
| General and administrative | 14,844 | 10,686 | 39,396 | 31,897 | |||||||||||||
| Total operating expenses | 82,251 | 73,617 | 247,346 | 201,638 | |||||||||||||
| Operating loss | (82,251 | ) | (73,617 | ) | (247,309 | ) | (200,214 | ) | |||||||||
| Investment and other income, net | 6,694 | 6,573 | 19,564 | 22,774 | |||||||||||||
| Net loss | $ | (75,557 | ) | $ | (67,044 | ) | $ | (227,745 | ) | $ | (177,440 | ) | |||||
| Basic and diluted net loss per common share | $ | (0.96 | ) | $ | (1.01 | ) | $ | (3.06 | ) | $ | (2.67 | ) | |||||
| Shares used in calculating basic and diluted net loss per share | 78,531 | 66,420 | 74,356 | 66,399 | |||||||||||||
| Condensed Consolidated Balance Sheet Data | September 30 | December 31 | |||||||
| 2026 | 2025 | ||||||||
| (Unaudited) | |||||||||
| Assets | |||||||||
| Cash, cash equivalents and marketable securities | $ | 650,319 | $ | 518,573 | |||||
| Other current assets | 13,417 | 16,091 | |||||||
| Property and equipment, net | 10,997 | 5,334 | |||||||
| Intangible and other assets, net | 46,798 | 42,985 | |||||||
| Total assets | $ | 721,531 | $ | 582,983 | |||||
| Liabilities and stockholders' equity | |||||||||
| Current liabilities | $ | 60,517 | $ | 50,991 | |||||
| Long-term liabilities | 11,545 | 4,827 | |||||||
| Stockholders' equity | 649,469 | 527,165 | |||||||
| Total liabilities and stockholders' equity | $ | 721,531 | $ | 582,983 | |||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Celldex's Phase 3 barzolvolimab CSU trials show?
Both Phase 3 trials met their primary and all key secondary endpoints across both dose groups. Efficacy persisted or deepened from Weeks 12 to 24, with a favorable reported safety profile through 24 weeks. Treatment continues through 52 weeks, and Celldex anticipates a biologics license application in 2027.
How long does Celldex expect its cash to fund operations?
Celldex expects its cash, cash equivalents and marketable securities to fund estimated working capital requirements and current planned operations through 2028. These holdings totaled $650.3 million at September 30, 2026, compared with $717.6 million at June 30, 2026.
What is Celldex studying in the CDX-622 asthma trial?
The ongoing open-label, single-dose Phase 1 study evaluates CDX-622 in adults with mild to moderate asthma. It assesses safety, the drug's biological effects, and how the body processes it.